Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Coherus BioSciences, Inc. (CHRS)

« Back to company index

CHRS Chatter Timeline

Stock Ticker for CHRS

Most Active Tweeters for CHRS

UserTweets
@TickerReport 8
@AmericanBanking 7
@kshahi 6
@Tickeron 5
@stockmktgenius 4

Recent Tweets for CHRS

Tickeron @Tickeron
$CHRS Coherus BioSciences (CHRS, $21.14) was the market's top weekly gainer, with a +9% jump. Expect an Uptrend con… https://t.co/3CBBrn4DFk
June 26th 2019, 9:06pm
macondailynews @macondailynews
-$0.27 EPS Expected for Coherus Biosciences Inc $CHRS This Quarter https://t.co/gIZ3vi0qD8
June 26th 2019, 10:06am
TickerReport @TickerReport
Analysts Anticipate Coherus Biosciences Inc $CHRS Will Post Earnings of -$0.27 Per Share https://t.co/AqZmfUIQ4G
June 26th 2019, 10:06am
AmericanBanking @AmericanBanking
Coherus Biosciences $CHRS – Analysts’ Recent Ratings Updates https://t.co/xiNtGCbAQo #stocks
June 26th 2019, 5:06am
ZolmaxNews @ZolmaxNews
Coherus Biosciences $CHRS Stock Rating Upgraded by BidaskClub https://t.co/ttbdt11Biv
June 26th 2019, 2:06am
TickerReport @TickerReport
Coherus Biosciences $CHRS Stock Rating Upgraded by BidaskClub https://t.co/4hHhWu6YRC
June 26th 2019, 2:06am
mspacey4415 @mspacey4415
$CHRS CEO speaks out. https://t.co/mLoSmSwaWE
June 25th 2019, 6:06pm
MarketSmith @MarketSmith
RT @ivanhoff2: $CHRS - volatile biotech trying to clear new 52-week highs today. Volume is still slim. Relative strength of 98. @MarketSmit…
June 25th 2019, 11:06am
ivanhoff2 @ivanhoff2
$CHRS - volatile biotech trying to clear new 52-week highs today. Volume is still slim. Relative strength of 98.… https://t.co/7gqxXuaNV4
June 25th 2019, 9:06am
TranscriptDaily @TranscriptDaily
Barclays Reiterates $30.00 Price Target for Coherus Biosciences $CHRS https://t.co/yt91Xa4zfb
June 25th 2019, 1:06am
stocknewstimes @stocknewstimes
Barclays Reiterates $30.00 Price Target for Coherus Biosciences $CHRS https://t.co/owWJGjD0iU
June 25th 2019, 1:06am
SleekMoneycom @SleekMoneycom
Barclays Reiterates $30.00 Price Target for Coherus Biosciences $CHRS https://t.co/5IiFYuPXCq #investing
June 25th 2019, 1:06am
larrywabrams @larrywabrams
@Coherus_Bio @WSJopinion $CHRS CEO Lanfear has chosen a "branded #biosimilars approach" with expensive sales costs.… https://t.co/erkTapP0VH
June 25th 2019, 12:06am
larrywabrams @larrywabrams
@kshahi @Coherus_Bio $CHRS CEO Lanfear has chosen a "branded #biosimilars approach" with expensive sales costs. SEE… https://t.co/wpwt7fFu20
June 25th 2019, 12:06am
stockmktgenius @stockmktgenius
$CHRS Coherus BioSciences, Inc. Top stock up 160% from low. Close: 21.34 VolvsAvg: 0.81 Liq: $16M https://t.co/PM5S1zW6Uw
June 24th 2019, 11:06pm
kshahi @kshahi
@larrywabrams @Coherus_Bio If you think UNH did this to lower "TREATMENT" cost, I have a bridge to sell you. $CHRS… https://t.co/llGQtpn95G
June 24th 2019, 8:06pm
TickerReport @TickerReport
Coherus Biosciences Inc $CHRS Director James Healy Sells 317,130 Shares https://t.co/mlO1rIOpZd
June 24th 2019, 8:06pm
AmericanBanking @AmericanBanking
Coherus Biosciences Inc $CHRS Director James Healy Sells 317,130 Shares https://t.co/I0N3hvm2EL #stocks
June 24th 2019, 8:06pm
InsiderAlertsIA @InsiderAlertsIA
$CHRS: New Insider Filing on Director JAMES HEALY: https://t.co/qSOkEq5ADQ
June 24th 2019, 6:06pm
fintel_io @fintel_io
Insider HEALY JAMES reports selling 317,130 shares of $CHRS for a total cost of $6,777,068.10 https://t.co/TTwdcF7M6M
June 24th 2019, 6:06pm
StockTexts @StockTexts
$CHRS Coherus BioSciences, Inc. SEC Filing: Form 4 https://t.co/tRcwkEx4C9
June 24th 2019, 6:06pm
TickerReport @TickerReport
Coherus Biosciences $CHRS PT Set at $30.00 by Barclays https://t.co/qVi10HHljV
June 24th 2019, 3:06pm
larrywabrams @larrywabrams
@Coherus_Bio $CHRS CEO Lanfear fails to consider that $UNH calculated that reference drug Neulasta, available as s… https://t.co/OK3XuL4jfA
June 24th 2019, 3:06pm
AmericanBanking @AmericanBanking
Coherus Biosciences $CHRS PT Set at $30.00 by Barclays https://t.co/KvE1ai0OZd #stocks
June 24th 2019, 3:06pm
HeadlinesFin @HeadlinesFin
Analysts at Robert W. Baird Maintained their Past ‘"Buy"’ rating on Shares Coherus Biosciences $CHRS, Set a $28 TP https://t.co/LzqbCFVNpT
June 24th 2019, 8:06am
registrarjourn @registrarjourn
Insider Selling: Coherus Biosciences Inc $CHRS CFO Sells $135,496.10 in Stock https://t.co/IVJowT8cIo
June 23rd 2019, 6:06am
EnterpriseLeade @EnterpriseLeade
Insider Selling: Coherus Biosciences Inc $CHRS CFO Sells $135,496.10 in Stock https://t.co/ai1H7blDzs
June 23rd 2019, 6:06am
TranscriptDaily @TranscriptDaily
Insider Selling: Coherus Biosciences Inc $CHRS CFO Sells $135,496.10 in Stock https://t.co/Znzug3YmuH
June 23rd 2019, 6:06am
TranscriptDaily @TranscriptDaily
Robert W. Baird Reiterates $28.00 Price Target for Coherus Biosciences $CHRS https://t.co/OG980geNDc
June 23rd 2019, 5:06am
registrarjourn @registrarjourn
Robert W. Baird Reiterates $28.00 Price Target for Coherus Biosciences $CHRS https://t.co/fAvUhFk3Mm
June 23rd 2019, 5:06am
EnterpriseLeade @EnterpriseLeade
Robert W. Baird Reiterates $28.00 Price Target for Coherus Biosciences $CHRS https://t.co/dSkOGv5Kb1
June 23rd 2019, 5:06am
AmericanBanking @AmericanBanking
$44.14 Million in Sales Expected for Coherus Biosciences Inc $CHRS This Quarter https://t.co/0JmyJYUmHQ #stocks
June 23rd 2019, 3:06am
TickerReport @TickerReport
Jean-Frederic Viret Sells 6,826 Shares of Coherus Biosciences Inc $CHRS Stock https://t.co/OL2xnvMASF
June 22nd 2019, 6:06am
WKRBNews @WKRBNews
Robert W. Baird Analysts Give Coherus Biosciences $CHRS a $28.00 Price Target https://t.co/fxafvGQRgL #markets
June 22nd 2019, 5:06am
TickerReport @TickerReport
Coherus Biosciences $CHRS PT Set at $28.00 by Robert W. Baird https://t.co/YGP5nWgPLs
June 22nd 2019, 5:06am
stockmktgenius @stockmktgenius
$CHRS Coherus BioSciences, Inc. Top stock up 160% from low. Close: 21.77 VolvsAvg: 1.21 Liq: $25M https://t.co/PM5S1zW6Uw
June 22nd 2019, 12:06am
Tickeron @Tickeron
$CHRS Coherus BioSciences (CHRS, $21.66) was the market's top weekly gainer, with a +19% jump. Expect an Uptrend co… https://t.co/xhMIIqcq5V
June 21st 2019, 7:06pm
kshahi @kshahi
$CHRS. https://t.co/Fn3LBnofuM
June 21st 2019, 4:06pm
AmericanBanking @AmericanBanking
Zacks: Brokerages Anticipate Coherus Biosciences Inc $CHRS Will Post Earnings of -$0.21 Per Share https://t.co/gLYXMrEyfZ #stocks
June 21st 2019, 2:06pm
Tickeron @Tickeron
$CHRS Coherus BioSciences (CHRS, $21.66) soars +51% and reaches a 3-month high https://t.co/ebjqYx3cp3
June 21st 2019, 11:06am
stellabystar1 @stellabystar1
$CHRS: a lil' more volume please... https://t.co/SMNQZj76AN
June 21st 2019, 10:06am
Quantumup1 @Quantumup1
$CHRS is in 'a league of its own,' says Barclays https://t.co/pzGRz8kZXz
June 21st 2019, 6:06am
registrarjourn @registrarjourn
Coherus Biosciences $CHRS Cut to “Hold” at BidaskClub https://t.co/Fj5Tra0N4t
June 21st 2019, 2:06am
EnterpriseLeade @EnterpriseLeade
Coherus Biosciences $CHRS Cut to “Hold” at BidaskClub https://t.co/JuefBvfZ8N
June 21st 2019, 2:06am
Tickeron @Tickeron
$CHRS Coherus BioSciences (CHRS, $20.67) was the market's top weekly gainer, with a +15% jump. Expect an Uptrend co… https://t.co/ZKqWpudHoq
June 20th 2019, 7:06pm
Tickeron @Tickeron
$CHRS Coherus BioSciences (CHRS, $20.67) soars +33% and reaches a 3-month high. Expect an Uptrend reversal https://t.co/6CLTK09mNe
June 20th 2019, 6:06pm
stockmktgenius @stockmktgenius
$CHRS Coherus BioSciences, Inc. Top stock up 158% from low. Close: 21.66 VolvsAvg: 1.60 Liq: $30M https://t.co/PM5S1zW6Uw
June 20th 2019, 5:06pm
AmericanBanking @AmericanBanking
Coherus Biosciences Inc $CHRS CFO Jean-Frederic Viret Sells 6,826 Shares https://t.co/kG0Rp0tqyQ #stocks
June 20th 2019, 5:06pm
dispatchtribune @dispatchtribune
Coherus Biosciences $CHRS Given a $28.00 Price Target at Robert W. Baird https://t.co/pQeWlCTEJr
June 20th 2019, 4:06pm
OlympiaReport @OlympiaReport
Coherus Biosciences $CHRS Given a $28.00 Price Target by Robert W. Baird Analysts https://t.co/oAS9wXk11E
June 20th 2019, 4:06pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.